Zhaoke Ophthalmology says presbyopia eye drop YUVEZZI meets primary endpoint in China Phase II trial

• Zhaoke Ophthalmology reported its YUVEZZI presbyopia eye drop met the primary endpoint in a China Phase II study.
• Results have been presented as completed Phase II findings, not flagged for a future scientific meeting.
• Trial outcome showed improved near-vision performance while preserving distance vision, with tolerability consistent with a favorable safety profile.
• Next step targets talks with China’s drug regulator to move the program into Phase III.
• YUVEZZI is a once-daily, preservative-free fixed-dose combination already cleared by the FDA in January 2026 for presbyopia.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zhaoke Ophthalmology Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260904-12321522), on September 04, 2026, and is solely responsible for the information contained therein.